YOUR BUSINESS AUTHORITY
Springfield, MO
Novo Nordisk's shares fell as much as 9% after an Alzheimer’s drug trial failed to hit its key target.
The trial was designed to test whether semaglutide, the active ingredient in Ozempic and Wegovy, would slow progression for Alzheimer’s disease.
The share dip put the company's stock at a four-year low.
Read more from CNBC.
Complete with a 45-foot pedestrian bridge, this project adds a 10-foot-wide walking trail in front of Nixa’s High Pointe Elementary School and Summit Intermediate School.
AI expert gives advice at SBJ's People You Need to Know
European-style Christmas market to make debut in Branson next week
Big Cedar Lodge golf courses place on Golfweek list
Original, historic Pipkin building up for sale
Pizza Hut co-founder Dan Carney dies
Annual downtown holiday events combine for Nov. 21 celebration